Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.40M | 15.04M | 13.25M | 10.41M | 6.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.15M | 42.48M | 67.59M | 59.52M | 51.73M |
| Operating Income | -46.15M | -42.48M | -67.59M | -59.52M | -51.73M |
| Income Before Tax | -43.44M | -55.47M | -81.66M | -75.96M | -69.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.44 | -55.47 | -81.66 | -75.96 | -69.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.44M | -55.47M | -81.66M | -75.96M | -69.17M |
| EBIT | -46.15M | -42.48M | -67.59M | -59.52M | -51.73M |
| EBITDA | -23.53M | -12.74M | -- | -- | -- |
| EPS Basic | -4.27 | -20.04 | -47.57 | -51.22 | -51.30 |
| Normalized Basic EPS | -2.67 | -12.52 | -29.73 | -32.01 | -32.06 |
| EPS Diluted | -4.27 | -20.04 | -47.57 | -51.22 | -51.30 |
| Normalized Diluted EPS | -2.67 | -12.52 | -29.73 | -32.01 | -32.06 |
| Average Basic Shares Outstanding | 60.91M | 42.81M | 25.46M | 8.08M | 5.34M |
| Average Diluted Shares Outstanding | 60.91M | 42.81M | 25.46M | 8.08M | 5.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |